Bandar Alqarni/X
Sep 29, 2025, 11:36
Bandar Alqarni: Smoflipid 20% Use in IVF Protocols
Bandar Alqarni, Pharmacist in Riyadh, shared a post on X:
“Smoflipid 20% is gaining attention for its off-label use in IVF protocols, especially in cases of Recurrent Implantation Failure (RIF) or Recurrent Pregnancy Loss (RPL).
It may help by:
- Reducing NK cell activity
- Enhancing immune tolerance
- Supporting embryo implantation
While not considered a formal treatment, it is an option in select cases after ruling out organic and chromosomal causes. Its use is under strict medical supervision, often as part of an integrated immunotherapy plan.
Always consult your fertility specialist.”
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Feb 4, 2026, 00:43Join the 2026 Rising Stars Webinar On February 11 – SSR
-
Feb 4, 2026, 00:18Dalia Alqarni: Urinary Incontinence’s Impact on Women’s Health
-
Feb 4, 2026, 00:16New Study Reveals IVF Success for Women With Endometriosis – Fertility Plus
-
Feb 4, 2026, 00:13Tamuka Chekero: Exploring Relational Autonomy in Infertility Across Cultures
-
Feb 2, 2026, 13:04Optimal GnRH Agonist Dosage for Oocyte Maturation – Fertility and Sterility
-
Feb 2, 2026, 12:39Family Planning Challenges for Women with Lupus – The Lupus Foundation of Australasia
-
Feb 2, 2026, 12:17Anis Feki: Innovative Strategies for Bowel Endometriosis Management
-
Feb 2, 2026, 12:10Revolutionizing Testicular Cell Cultivation with 3D Bioprinting – School of Infection, Inflammation and Immunology, University of Birmingham
-
Feb 2, 2026, 12:07Cesar Diaz Garcia: Age and Its Impact on Male Fertility